Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors

doi:10.1158/1078-0432.CCR-15-1915

	Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors
	Ortiz-Cuaran, Sandra 1; Scheffler, Matthias 2,3; Plenker, Dennis 1,4; Dahmen, Ilona 1; Scheel, Andreas H.5; Fernandez-Cuesta, Lynnette 1,6; Meder, Lydia 5; Lovly, Christine M.7; Persigehl, Thorsten 8; Merkelbach-Bruse, Sabine 5; Bos, Marc 1; Michels, Sebastian 2,3; Fischer, Rieke 2,3; Albus, Kerstin 5; Koenig, Katharina 9; Schildhaus, Hans-Ulrich 10; Fassunke, Jana 5; Ihle, Michaela A.5; PasternackO, Helen 5,11,12,13,14; Heydt, Carina 5; Becker, Christian 15; Altmueller, Janine 15; Ji, Hongbin16,17 ; Mueller, Christian 1; Florin, Alexandra 5; Heuckmann, Johannes M.18; Nuernberg, Peter 15; Ansen, Sascha 2,3; Heukamp, Lukas C.5,18; Berg, Johannes 19; Pao, William 7; Peifer, Martin 1,20; Buettner, Reinhard 5; Wolfe, Juergen 2,3; Thomas, Roman K.1,5; Sos, Martin L.4
	2016-10
发表期刊	CLINICAL CANCER RESEARCH
ISSN	1078-0432
卷号	22 期号:19 页码:4837-4847
发表状态	已发表
DOI	10.1158/1078-0432.CCR-15-1915
摘要	Purpose: To identify novel mechanisms of resistance to third-generation EGFR inhibitors in patients with lung adenocarcinoma that progressed under therapy with either AZD9291 or rociletinib (CO-1686).
收录类别	SCI
语种	英语
资助项目	[SFB832]
WOS研究方向	Oncology
WOS类目	Oncology
WOS记录号	WOS:000385630500011
出版者	AMER ASSOC CANCER RESEARCH
WOS关键词	GROWTH-FACTOR RECEPTOR ; CELL LUNG-CANCER ; KINASE INHIBITORS ; MET AMPLIFICATION ; CONFERS RESISTANCE ; KRAS MUTATION ; AZD9291 ; MUTANT ; GEFITINIB ; ERLOTINIB
原始文献类型	Article
引用统计
文献类型	期刊论文
条目标识符	https://kms.shanghaitech.edu.cn/handle/2MSLDSTB/1689
专题	生命科学与技术学院_特聘教授组_季红斌组
通讯作者	Buettner, Reinhard; Wolfe, Juergen; Thomas, Roman K.; Sos, Martin L.
作者单位	1.Univ Cologne, Fac Med, Ctr Integrated Oncol Cologne Bonn, Dept Translat Genom, Cologne, Germany 2.Univ Hosp Cologne, Ctr Integrated Oncol Cologne Bonn, Lung Canc Grp Cologne, Dept Internal Med 1, Cologne, Germany 3.Univ Hosp Cologne, Ctr Integrated Oncol Cologne Bonn, Network Genom Med Lung Canc, Cologne, Germany 4.Univ Hosp Cologne, Ctr Integrated Oncol, Mol Pathol, Cologne, Germany 5.Univ Hosp Cologne, Inst Pathol, Ctr Integrated Oncol, Cologne, Germany 6.Int Agcy Res Canc IARC WHO, Genet Sect, Genet Canc Susceptibil Grp, Lyon, France 7.Vanderbilt Univ, Dept Med, Nashville, TN USA 8.Univ Hosp Cologne, Dept Radiol, Cologne, Germany 9.Labor Dr Quade & Kollegen GmbH, Cologne, Germany 10.Univ Hosp Gottingen, Inst Pathol, Gottingen, Germany 11.Univ Hosp Luebeck, Pathol, Lubeck, Germany 12.Leibniz Res Ctr Borstel, Lubeck, Germany 13.Univ Hosp Luebeck, Pathol, Borstel, Germany 14.Leibniz Res Ctr Borstel, Borstel, Germany 15.Univ Cologne, CCG, Cologne, Germany 16.Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol,CAS Ctr Excellence Mol C, Innovat Ctr Cell Signaling Network,Key Lab Syst B, Shanghai, Peoples R China 17.Shanghai Tech Univ, Sch Life Sci & Technol, Shanghai, Peoples R China 18.NEO New Oncol AG, Cologne, Germany 19.Univ Cologne, Inst Theoret Phys, Cologne, Germany 20.Univ Cologne, CMMC, Cologne, Germany
推荐引用方式 GB/T 7714	Ortiz-Cuaran, Sandra,Scheffler, Matthias,Plenker, Dennis,et al. Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors[J]. CLINICAL CANCER RESEARCH,2016,22(19):4837-4847.
APA	Ortiz-Cuaran, Sandra.,Scheffler, Matthias.,Plenker, Dennis.,Dahmen, Ilona.,Scheel, Andreas H..,...&Sos, Martin L..(2016).Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors.CLINICAL CANCER RESEARCH,22(19),4837-4847.
MLA	Ortiz-Cuaran, Sandra,et al."Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors".CLINICAL CANCER RESEARCH 22.19(2016):4837-4847.